{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:48:44Z","timestamp":1791877724008,"version":"4.3.4"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.jns.2026.126210","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:12:28Z","timestamp":1791501148000},"page":"126210","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Long-term outcomes of alemtuzumab in relapsing\u2013remitting multiple sclerosis: a real-world cohort with particular focus on treatment sequencing after natalizumab"],"prefix":"10.1016","volume":"491","author":[{"given":"Marta","family":"Gaggiola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina Annamaria","family":"Mauceri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Zanotelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Zoccarato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Rinaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Perini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Puthenparampil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2026.126210_bb0005","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419836913","article-title":"Pulsed immune reconstitution therapy in multiple sclerosis","volume":"12","author":"Sorensen","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"6","key":"10.1016\/j.jns.2026.126210_bb0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039416","article-title":"Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis","volume":"7","author":"Rao","year":"2012","journal-title":"PLoS One"},{"issue":"50","key":"10.1016\/j.jns.2026.126210_bb0015","doi-asserted-by":"crossref","first-page":"20200","DOI":"10.1073\/pnas.1313654110","article-title":"Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation","volume":"110","author":"Jones","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.jns.2026.126210_bb0020","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10875-009-9327-3","article-title":"B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis","volume":"30","author":"Thompson","year":"2010","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.jns.2026.126210_bb0025","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1509987","article-title":"The immunological bases of alemtuzumab as induction-therapy in pediatric-onset multiple sclerosis","volume":"15","author":"Puthenparampil","year":"2025","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.jns.2026.126210_bb0030","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1093\/brain\/awac064","article-title":"Alemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunity","volume":"145","author":"Ruck","year":"2022","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.jns.2026.126210_bb0035","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12051768","article-title":"Alemtuzumab-related lymphocyte subset dynamics and disease activity or autoimmune adverse events: real-world evidence","volume":"12","author":"Signoriello","year":"2023","journal-title":"J. Clin. Med."},{"issue":"1","key":"10.1016\/j.jns.2026.126210_bb0040","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000420","article-title":"Evidence of B-cell dysregulation in severe CNS inflammation after alemtuzumab therapy","volume":"5","author":"Rinaldi","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"4","key":"10.1016\/j.jns.2026.126210_bb0045","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S1474-4422(19)30076-6","article-title":"Intracerebral haemorrhage during alemtuzumab administration","volume":"18","author":"Azevedo","year":"2019","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2026.126210_bb0050","series-title":"FDA Warns About Rare But Serious Risks of Stroke and Blood Vessel Wall Tears With Multiple Sclerosis Drug Lemtrada (Alemtuzumab)","author":"Anon","year":"2026"},{"key":"10.1016\/j.jns.2026.126210_bb0055","series-title":"Lemtrada - referral","author":"Anon","year":"2025"},{"issue":"2","key":"10.1016\/j.jns.2026.126210_bb0060","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jns.2026.126210_bb0065","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418805713","article-title":"NEDA-3 status including cortical lesions in the comparative evaluation of natalizumab versus fingolimod efficacy in multiple sclerosis","volume":"11","author":"Puthenparampil","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.jns.2026.126210_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2026.107148","article-title":"EDSS and disease duration associate with progression independent of relapse and MRI activity in natalizumab-treated multiple sclerosis patients","volume":"109","author":"Puthenparampil","year":"2026","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"11","key":"10.1016\/j.jns.2026.126210_bb0075","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1001\/jamaneurol.2023.3331","article-title":"Harmonizing definitions for progression independent of relapse activity in multiple sclerosis: a systematic review","volume":"80","author":"M\u00fcller","year":"2023","journal-title":"JAMA Neurol."},{"issue":"3","key":"10.1016\/j.jns.2026.126210_bb0080","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.jns.2026.126210_bb0085","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1093\/brain\/awac016","article-title":"How patients with multiple sclerosis acquire disability","volume":"145","author":"Lublin","year":"2022","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.jns.2026.126210_bb0090","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209444","article-title":"Using the progression independent of relapse activity framework to unveil the pathobiological foundations of multiple sclerosis","volume":"103","author":"Ciccarelli","year":"2024","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.jns.2026.126210_bb0095","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1007\/s40120-023-00549-7","article-title":"No evidence of disease activity (NEDA) as a clinical assessment tool for multiple sclerosis: clinician and patient perspectives [narrative review]","volume":"12","author":"Newsome","year":"2023","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.jns.2026.126210_bb0100","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3389\/fneur.2021.620758","article-title":"Alemtuzumab in a large real-life cohort: interim baseline data of the TREAT-MS study","volume":"12","author":"Ziemssen","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jns.2026.126210_bb0105","doi-asserted-by":"crossref","DOI":"10.1177\/17562864231194823","article-title":"Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study","volume":"16","author":"Coles","year":"2023","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"9","key":"10.1016\/j.jns.2026.126210_bb0110","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s40263-020-00749-x","article-title":"Efficacy and safety of alemtuzumab through 9 years of follow-up in patients with highly active disease: post hoc analysis of CARE-MS I and II patients in the TOPAZ extension study","volume":"34","author":"Ziemssen","year":"2020","journal-title":"CNS Drugs"},{"issue":"17","key":"10.1016\/j.jns.2026.126210_bb0115","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abn1823","article-title":"Identification of four novel T cell autoantigens and personal autoreactive profiles in multiple sclerosis","volume":"8","author":"Bronge","year":"2022","journal-title":"Sci. Adv."},{"issue":"6","key":"10.1016\/j.jns.2026.126210_bb0120","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001075","article-title":"T-cell specificity influences disease heterogeneity in multiple sclerosis","volume":"8","author":"Cruciani","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jns.2026.126210_bb0125","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.706278","article-title":"Immune regulatory cell bias following alemtuzumab treatment in relapsing-remitting multiple sclerosis","volume":"12","author":"Kashani","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.jns.2026.126210_bb0130","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/imm.12178","article-title":"Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro","volume":"141","author":"Havari","year":"2014","journal-title":"Immunology"},{"key":"10.1016\/j.jns.2026.126210_bb0135","doi-asserted-by":"crossref","first-page":"1249201","DOI":"10.3389\/fimmu.2023.1249201","article-title":"Immune reconstitution following alemtuzumab therapy is characterized by exhausted T cells, increased regulatory control of proinflammatory T cells and reduced B cell control","volume":"14","author":"von Essen","year":"2023","journal-title":"Front. Immunol."},{"issue":"9856","key":"10.1016\/j.jns.2026.126210_bb0140","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet"},{"issue":"9856","key":"10.1016\/j.jns.2026.126210_bb0145","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jns.2026.126210_bb0150","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241306575","article-title":"Long-term efficacy and safety of alemtuzumab in participants with highly active MS: TOPAZ clinical trial and interim analysis of TREAT-MS real-world study","volume":"18","author":"Ziemssen","year":"2025","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"11","key":"10.1016\/j.jns.2026.126210_bb0155","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1007\/s00415-020-09983-1","article-title":"Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223","volume":"267","author":"Steingo","year":"2020","journal-title":"J. Neurol."},{"issue":"5","key":"10.1016\/j.jns.2026.126210_bb0160","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s13760-024-02542-9","article-title":"Long-term follow up of alemtuzumab-treated patients: a retrospective study in a Belgian tertiary care center","volume":"124","author":"van Pesch","year":"2024","journal-title":"Acta Neurol. Belg."},{"issue":"2","key":"10.1016\/j.jns.2026.126210_bb0165","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1007\/s00415-021-10664-w","article-title":"Safety of alemtuzumab in a nationwide cohort of Finnish multiple sclerosis patients","volume":"269","author":"Rauma","year":"2022","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.jns.2026.126210_bb0170","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/ene.15121","article-title":"A real-world study of alemtuzumab in a cohort of Italian patients","volume":"29","author":"Russo","year":"2022","journal-title":"Eur. J. Neurol."},{"issue":"6","key":"10.1016\/j.jns.2026.126210_bb0175","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s00415-019-09272-6","article-title":"Efficacy and safety of alemtuzumab in a real-life cohort of patients with multiple sclerosis","volume":"266","author":"Frau","year":"2019","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.jns.2026.126210_bb0180","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s40263-024-01066-3","article-title":"Real-world retrospective analysis of alemtuzumab outcomes in relapsing-remitting multiple sclerosis: the LEMCAM study","volume":"38","author":"Costa-Frossard Fran\u00e7a","year":"2024","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jns.2026.126210_bb0185","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1265354","article-title":"A five-year observational prospective mono-center study of the efficacy of alemtuzumab in a real-world cohort of patients with multiple sclerosis","volume":"14","author":"Sandgren","year":"2023","journal-title":"Front. Neurol."},{"issue":"9","key":"10.1016\/j.jns.2026.126210_bb0190","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1177\/1352458515614092","article-title":"Alemtuzumab for multiple sclerosis: long term follow-up in a multi-centre cohort","volume":"22","author":"Willis","year":"2015","journal-title":"Mult. Scler. J."},{"issue":"4","key":"10.1016\/j.jns.2026.126210_bb0195","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1474-4422(17)30007-8","article-title":"Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study","volume":"16","author":"Kalincik","year":"2017","journal-title":"Lancet Neurol."},{"issue":"6","key":"10.1016\/j.jns.2026.126210_bb0200","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ana.20703","article-title":"Diagnostic criteria for multiple sclerosis: 2005 revisions to the \u2018McDonald Criteria\u2019","volume":"58","author":"Polman","year":"2005","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jns.2026.126210_bb0205","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.msard.2019.03.002","article-title":"Alemtuzumab as rescue therapy in case of multiple sclerosis rebound following natalizumab break: clinical case and literature review","volume":"30","author":"Federle","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jns.2026.126210_bb0210","doi-asserted-by":"crossref","DOI":"10.1177\/17562864231177196","article-title":"Alemtuzumab following natalizumab is more effective in adult-onset than paediatric-onset multiple sclerosis","volume":"16","author":"Puthenparampil","year":"2023","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"8","key":"10.1016\/j.jns.2026.126210_bb0215","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1177\/13524585241261565","article-title":"Safety and effectiveness of disease-modifying therapies after switching from natalizumab","volume":"30","author":"Zeineddine","year":"2024","journal-title":"Mult. Scler. J."},{"issue":"1","key":"10.1016\/j.jns.2026.126210_bb0220","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s40120-016-0058-0","article-title":"High-risk PML patients switching from natalizumab to alemtuzumab: an observational study","volume":"6","author":"Malucchi","year":"2017","journal-title":"Neurol. Ther."},{"issue":"4","key":"10.1016\/j.jns.2026.126210_bb0225","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1007\/s40120-025-00754-6","article-title":"Disease course in patients switched from natalizumab to alemtuzumab: an Italian multicenter, prospective, observational study","volume":"14","author":"Malucchi","year":"2025","journal-title":"Neurol. Ther."},{"issue":"1","key":"10.1016\/j.jns.2026.126210_bb0230","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00415-018-9117-z","article-title":"Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation","volume":"266","author":"Pfeuffer","year":"2019","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.jns.2026.126210_bb0235","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cell.2018.08.011","article-title":"Memory B cells activate brain-homing, autoreactive CD4+ T cells in multiple sclerosis","volume":"175","author":"Jelcic","year":"2018","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.jns.2026.126210_bb0240","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S1474-4422(16)30382-9","article-title":"Severe B-cell-mediated CNS disease secondary to alemtuzumab therapy","volume":"16","author":"Haghikia","year":"2017","journal-title":"Lancet Neurol."},{"issue":"9 Suppl 2","key":"10.1016\/j.jns.2026.126210_bb0245","first-page":"S12","article-title":"Immunopathophysiology of pediatric CNS inflammatory demyelinating diseases","volume":"87","author":"Bar-Or","year":"2016","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.jns.2026.126210_bb0250","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1177\/1352458519851219","article-title":"Emerging safety issues in alemtuzumab-treated MS patients","volume":"25","author":"Killestein","year":"2019","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2026.126210_bb0255","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1495529","article-title":"The role of microglia in multiple sclerosis: implications for treatment with Bruton\u2019s tyrosine kinase inhibitors","volume":"16","author":"Vermersch","year":"2025","journal-title":"Front. Immunol."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X26004922?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X26004922?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:21:28Z","timestamp":1791876088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X26004922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":51,"alternative-id":["S0022510X26004922"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2026.126210","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term outcomes of alemtuzumab in relapsing\u2013remitting multiple sclerosis: a real-world cohort with particular focus on treatment sequencing after natalizumab","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2026.126210","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"126210"}}